NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Acacia Communications, Inc. (“Acacia” or the “Company”) (NASDAQ: ACIA) securities and certain of its officers, on behalf of a class who purchased Acacia shares between August 11, 2016, and July 13, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acia.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Acacia’s manufacturing and quality control processes were deficient; (2) the foregoing deficiencies were likely to disrupt the Company’s manufacturing, thereby impacting the Company’s revenues; and (3) consequently, Acacia’s public statements were materially false and misleading at all relevant times.

On May 31, 2017, Acacia announced that “the Company has identified a quality issue” impacting “a portion” of several thousand modules manufactured by one of Acacia’s three contract manufacturers, citing as the “root cause of this quality issue . . . a circuit board cleaning process that has since been eliminated.” On July 14, 2017, Acacia revealed its preliminary financial and operating results for the quarter ended June 30, 2017, reporting that its profit and revenue were short of projections, and the Company revised its current-quarter guidance downward. Acacia stated that its “second-quarter results were adversely affected by the quality issue identified at one of our three contract manufacturers that we announced on May 31.” Following this news, Acacia stock has dropped $2.62 per share, or 6.30%, to close at $39.00 per share on July 14, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/acia or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Acacia you have until October 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 476504

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ: IPCI) and certain of its officers, on behalf of shareholders who purchased IntelliPharmaCeutics securities between January 14, 2016 and July 26, 2016, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ipci.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) Intellipharmaceutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; (3) Intellipharmaceutics was not submitting sufficient data to support approval of the NDA; and (4) consequently, defendants’ statements about the Company’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On July 27, 2017, the FDA published a report revealing that, “The safety information collected in the pharmacokinetic studies was of limited value…” Following this news, Intellipharmaceutics stock dropped over 45% to close at $1.36 per share on July 27, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/ipci, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Intellipharmaceutics, you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 470863

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TechnipFMC plc (NYSE: FTI) who purchased shares between April 27, 2017 and July 24, 2017. The action, which was filed in the United States District Court for the Southern District of Texas, Houston Division, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) TechnipFMC had a material weakness in its internal control over rates used in the calculations of the foreign currency effects on certain of its engineering and construction projects; (ii) accordingly, the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, TechnipFMC’s public statements were materially false and misleading at all relevant times.

Shareholders have until October 2, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/technipfmc-plc?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 476584

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) securities and certain of its officers, on behalf of a class who purchased Acacia shares between May 31, 2016, and September 20, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/icpt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Ocaliva entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result of the foregoing, Intercept’s public statements were materially false and misleading at all relevant times.

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva, advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.

On this news, Intercept’s share price fell $15.36, or 13.53%, to close at $98.12 on September 12, 2017.

On September 21, 2017, the FDA issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug.

On this news, Intercept’s share price fell $24.42, or 24.88%, to close at $73.70 on September 21, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/icpt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Intercept you have until November 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 476510

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Envision Healthcare Corporation (NYSE: EVHC) who purchased shares between March 2, 2015 and July 21, 2017. The action, which was filed in the United States District Court for the Middle District of Tennessee, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Envision Healthcare subsidiary EmCare Holdings, Inc. routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.

Shareholders have until October 3, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the Class Period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/envision-healthcare-corporation?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 476586

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Forterra, Inc. (“Forterra” or the “Company”) (NASDAQ: FRTA) securities and certain of its officers, on behalf of a class who purchased Forterra common stock issued in connection with the Company’s October 21, 2016 initial public offering (the “IPO”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/frta.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934

The complaint alleges that the Registration Statement issued in connection with the IPO contained inaccurate statements and omitted facts necessary to make other statements made therein not misleading. Specifically, the complaint alleges that: (1) the Registration Statement failed to disclose, at the time of the IPO, that organic sales in Forterra’s Drainage and Water segments had significantly declined; (2) that Forterra was experiencing increased pricing pressure due to competition and continued softness in its concrete and steel pipe business; (3) that Forterra had been losing business in its important pipe and precast business due to in large part to operational problems at its production plants; and (4) that Forterra had undisclosed material weaknesses in its internal controls that prevented it from accurately reporting and forecasting its financial results.

Forterra’s IPO was successful and the underwriters, who sold 18.42 million shares of Forterra common stock to the public at $18 per share, raised over $331 million in gross proceeds. Once true details regarding the Company’s business and finances were made public, Forterra common stock dropped and now trades at roughly 75% of its IPO price.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/frta or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Forterra you have until October 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 476507

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE: EVHC) and certain of its officers, on behalf of shareholders who purchased Envision securities between March 2, 2015 and July 21, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/evhc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Envision’s operating subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (3) Envision’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (4) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (5) consequently, Envision’s public statements were materially false and misleading at all relevant times.

On July 24, 2017, The New York Times published an article stating that doctors associated with Envision’s subsidiary EmCare Holdings Inc. were extremely likely to engage in “surprise billing,” in which patients who go to in-network hospitals are treated by out-of-network doctors and then billed at higher rates. Following this news, Envision stock dropped $2.33 per share, or 3.72%, to close at $60.28 on July 24, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/evhc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Envision, you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 473297

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc. (NASDAQ: IPCI) between May 21, 2015 and July 26, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Shanawaz v. Intellipharmaceutics International Inc., et al. (Case No. 1:17-cv-05761) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information, go to:

http://www.zlk.com/pslra-sbm/intellipharmaceutics-international-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On July 27, 2017, shares of Intellipharmaceutics fell when the FDA released a report disclosing that, “The safety information collected in the pharmacokinetic studies was of limited value…”

If you suffered a loss in Intellipharmaceutics, you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476577